These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32433551)

  • 1. Association between pachychoroid and long-term treatment outcomes of photodynamic therapy with intravitreal ranibizumab for polypoidal choroidal vasculopathy.
    Azuma K; Okubo A; Nomura Y; Zhou H; Terao R; Hashimoto Y; Asano KS; Azuma K; Inoue T; Obata R
    Sci Rep; 2020 May; 10(1):8337. PubMed ID: 32433551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen.
    Lai K; Li Y; Zhou L; Zhong X; Huang C; Xu F; Lu L; Ge J; Jin C
    BMC Ophthalmol; 2018 Jun; 18(1):144. PubMed ID: 29925341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic changes in choroidal conditions during anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy.
    Nagai N; Suzuki M; Minami S; Kurihara T; Kamoshita M; Sonobe H; Watanabe K; Uchida A; Shinoda H; Tsubota K; Ozawa Y
    Sci Rep; 2019 Aug; 9(1):11389. PubMed ID: 31388029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CHOROIDAL THICKNESS AS A PROGNOSTIC FACTOR OF PHOTODYNAMIC THERAPY WITH AFLIBERCEPT OR RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Sakurada Y; Sugiyama A; Tanabe N; Kikushima W; Kume A; Iijima H
    Retina; 2017 Oct; 37(10):1866-1872. PubMed ID: 28002268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY: The Fujisan Study.
    Gomi F; Oshima Y; Mori R; Kano M; Saito M; Yamashita A; Iwata E; Maruko R;
    Retina; 2015 Aug; 35(8):1569-76. PubMed ID: 25830698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-year visual outcomes of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy.
    Sakai T; Okano K; Kohno H; Tsuneoka H
    Acta Ophthalmol; 2016 Dec; 94(8):e765-e771. PubMed ID: 27237048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports.
    Iesato Y; Tanaka M; Murata M; Kitahara J; Hirano T; Kurenuma T; Yoshida N; Murata T
    BMC Ophthalmol; 2018 Nov; 18(1):284. PubMed ID: 30390650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy.
    Wong IY; Shi X; Gangwani R; Zhao P; Iu LP; Li Q; Ng A; Li X
    BMC Ophthalmol; 2015 Jun; 15():66. PubMed ID: 26122636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
    Koh A; Lai TYY; Takahashi K; Wong TY; Chen LJ; Ruamviboonsuk P; Tan CS; Feller C; Margaron P; Lim TH; Lee WK;
    JAMA Ophthalmol; 2017 Nov; 135(11):1206-1213. PubMed ID: 28983556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy.
    Inoue M; Arakawa A; Yamane S; Kadonosono K
    Eye (Lond); 2013 Sep; 27(9):1013-20; quiz 1021. PubMed ID: 23970023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of one-year results of photodynamic therapy combined with ranibizumab or aflibercept for treating polypoidal choroidal vasculopathy.
    Ito A; Maruyama-Inoue M; Kitajima Y; Sato S; Inoue T; Yamane S; Kadonosono K
    PLoS One; 2020; 15(6):e0235213. PubMed ID: 32579608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians.
    Fenner BJ; Ting DSW; Tan ACS; Teo K; Chan CM; Mathur R; Yeo IYS; Wong TY; Wong EYM; Cheung CMG
    Ophthalmol Retina; 2020 Apr; 4(4):403-414. PubMed ID: 31953109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome.
    Kang HM; Koh HJ; Lee CS; Lee SC
    Am J Ophthalmol; 2014 Mar; 157(3):598-606.e1. PubMed ID: 24269378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing efficacy of reduced-fluence and standard-fluence photodynamic therapy in the treatment of polypoidal choroidal vasculopathy.
    Ngo WK; Chee WK; Tan CS; Lim TH
    BMC Ophthalmol; 2020 Apr; 20(1):150. PubMed ID: 32293353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Jain P; Anantharaman G; Gopalakrishnan M; Goyal A
    Indian J Ophthalmol; 2018 Aug; 66(8):1119-1127. PubMed ID: 30038155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial treatment for polypoidal choroidal vasculopathy: Ranibizumab combined with photodynamic therapy or fixed-dosing aflibercept monotherapy.
    Yoneda A; Wakiyama H; Kurihara J; Kitaoka T
    Eur J Ophthalmol; 2020 Nov; 30(6):1473-1479. PubMed ID: 31476891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct Responsiveness to Intravitreal Ranibizumab Therapy in Polypoidal Choroidal Vasculopathy With Single or Multiple Polyps.
    Suzuki M; Nagai N; Shinoda H; Uchida A; Kurihara T; Tomita Y; Kamoshita M; Iyama C; Tsubota K; Ozawa Y
    Am J Ophthalmol; 2016 Jun; 166():52-59. PubMed ID: 27017997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial.
    Lim TH; Lai TYY; Takahashi K; Wong TY; Chen LJ; Ruamviboonsuk P; Tan CS; Lee WK; Cheung CMG; Ngah NF; Patalauskaite R; Margaron P; Koh A;
    JAMA Ophthalmol; 2020 Sep; 138(9):935-942. PubMed ID: 32672800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retreatment of polypoidal choroidal vasculopathy after photodynamic therapy combined with intravitreal ranibizumab.
    Kikushima W; Sakurada Y; Sugiyama A; Tanabe N; Yoneyama S; Iijima H
    Jpn J Ophthalmol; 2017 Jan; 61(1):61-66. PubMed ID: 27663239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the 12-Month Outcomes of Intravitreal Ranibizumab between Two Angiographic Subtypes of Polypoidal Choroidal Vasculopathy.
    Nakai S; Honda S; Miki A; Matsumiya W; Nakamura M
    Ophthalmologica; 2017; 237(3):123-127. PubMed ID: 28324878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.